NCT04634565View on ClinicalTrials.gov

PHARMACOKINETIC CHARACTERIZATION OF PF-06651600 IN CHINESE ADULT PARTICIPANTS

PHASE1CompletedINTERVENTIONAL

Enrollment

9

Participants

Timeline

Start Date

October 15, 2020

Primary Completion Date

November 19, 2020

Study Completion Date

November 19, 2020

Conditions

Healthy Participants

Interventions

DRUG

PF-06651600

oral PF-06651600 tablet 200 mg once daily

Trial Locations (2)

100089

North District of Peking University Third Hospital, Beijing

100191

Peking University Third Hospital, Beijing

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Pfizer

INDUSTRY